Prescient Therapeutics Release Amended Appendix 3B – Rights Issue

Melbourne, Australia (27 March 2019): Prescient Therapeutics Limited (ACN 006 569 106) (ASX: PTX), a clinical stage oncology company, provides the attached amended Appendix 3B in relation to the Nonrenounceable Rights Issue to existing shareholders which was announced on 25 March 2019.

The pro-rata non-renounceable rights issue (Rights Issue) of ordinary shares in the Company (Shares) is being offered on a one-for-five basis at an issue price of $0.05 per Share (Offer Price), and one attaching new option (New Option) for every two New Shares subscribed for under the Rights Issue with an exercise price of $0.0625 per New Option and exercisable on 31 March 2023.

View the Amended Appendix 3B – Rights Issue


About Prescient Therapeutics (ASX: PTX, Prescient):

Prescient Therapeutics is developing drugs to treat a range of cancers with significant unmet need. Prescient has one of the deepest clinical pipelines on the ASX, with two drugs that turn off “master switches” that are known to drive cancer.

Exciting interim breast cancer data for PTX-200 has exhibited twice the effectiveness of standard therapy. A new transformative trial for PTX-100 will also soon commence.

Register Interest